Cepheid, FIND to Evaluate Point-of-Care MDx System, TB Test | GenomeWeb

NEW YORK (GenomeWeb) – Cepheid said today that it is broadening its collaboration with the Foundation for Innovative New Diagnostics to bring point-of-care tuberculosis diagnostics to all levels of the health system in low- and middle-income countries.

Specifically, the partners will evaluate the performance of Cepheid's new GeneXpert Omni system and Xpert MTB/RIF Ultra test, and assess the Omni's cloud-based connectivity. All resulting data from the evaluation will be made publicly available, Cepheid said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.